Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biohaven Posts Positive Migraine Results, But Investors Are Wary

Mar 27 2018

• By Mandy Jackson

MR image of Human brain

Related Content

Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis

Mar 15 2018

10 First Approvals To Look Out For In 2018

Feb 02 2018

Bad News Teva Really Doesn't Need: A Potential Delay For Fremanezumab

Feb 08 2018

Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race

Sep 30 2016

Telcagepant failure is a headache for Merck (and perhaps Pfizer) but a break for others

Aug 01 2011

Allergan migraine portfolio grows with Merck CGRP antagonists

Jul 08 2015

Allergan Touts Ubrogepant Phase III Success, But Liver Tox Concerns Overhang

Feb 06 2018

Deal Watch: Fresenius Buyout Of Akorn Potentially Threatened By Data Integrity Issues

Feb 27 2018

Related Companies

Biohaven Pharmaceutical Holding Company Ltd.

Allergan plc

Amgen, Inc.

Novartis AG

Eli Lilly and Company

Teva Pharmaceutical Industries Ltd.

Bristol Myers Squibb Company

Catalent, Inc

Merck & Co., Inc.

Additional Topics

Clinical Trials Business Strategies Research & Development Neurology BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window